462

Compound name
Umbralisib
Alt Name
TGR-1202
rp-5264
TGR1202
Compound Image
Umbralisib.png
SMILES
CC(C)OC1=C(C=C(C=C1)C2=NN(C3=NC=NC(=C23)N)C(C)C4=C(C(=O)C5=C(O4)C=CC(=C5)F)C6=CC(=CC=C6)F)F
MW
571.50
Brutto
C31H24F3N5O3
InChI
InChI=1S/C31H24F3N5O3/c1-15(2)41-24-9-7-18(12-22(24)34)27-26-30(35)36-14-37-31(26)39(38-27)16(3)29-25(17-5-4-6-19(32)11-17)28(40)21-13-20(33)8-10-23(21)42-29/h4-16H,1-3H3,(H2,35,36,37)/t16-/m0/s1
InChI Key
IUVCFHHAEHNCFT-INIZCTEOSA-N
Approval Jurisdiction
2019 FDA
Approved for clinical use
Marginal Zone Lymphoma
CAS
1532533-67-7
PubChem CID
72950888
Action
PI3Kδ
Approved Drug List
1
Commercial Vendor
TG Therapeutic